Why Tracer?

Fastest In-Human

Accelerating decisions by imaging drug binding

Learn how
Latest news | See all news

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques.

By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process.

We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable.

Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.



Gerard: ‘We both knew that what we were about to do could change the world’

Tessa Aminetzah
Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
Floris Jan Voskuil, Steven Jakob de Jongh, Wouter Tjerk Rudolph Hooghiemstra, Matthijs David Linssen, Pieter Jan Steinkamp, Sebastiaan Antonius Hendrik Johannes de Visscher, Kees-Pieter Schepman, Sjoerd Geert Elias, Gert-Jan Meersma, Pascal Klaas Christiaan Jonker, Jan Johannes Doff, Annelies Jorritsma-Smit, Wouter Bastiaan Nagengast, Bert van der Vegt, Dominic James Robinson, Gooitzen Michell van Dam, Max Johannes Hendrikus Witjes
Theranostics 2020; 10(9): 3994-4005. doi:10.7150/thno.43227

Meet us.

Meet up with our team at the upcoming events.